Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
Earnings Data
Report Date
Aug 27, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.16Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 03, 2025
|% Change Since: -22.32%
|Next Earnings Date:Aug 27, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strategic advancements, new partnerships, and operational improvements, but was weighed down by decreased quarterly revenue and a significant net loss. The company remains optimistic about future growth and financial recovery.Company Guidance
During Lifecore Biomedical's fiscal 2025 third quarter earnings call, the company reported revenues of $35.2 million, marking a 2% decrease from the prior year's $35.7 million. This decline was primarily attributed to a $1.5 million reduction in CDMO revenues, offset by a $1 million increase in hyaluronic acid manufacturing revenues. Gross profit for the quarter was $9.8 million, compared to $11.9 million in the previous year, with the net loss recorded at $14.8 million, contrasting sharply with a net income of $15.6 million from the same period last year. Selling, general, and administrative expenses totaled $10.1 million, slightly up from $9.8 million, driven by increased litigation expenses. Adjusted EBITDA was reported at $5.7 million, down from $6.4 million in the prior year. The company's guidance for fiscal 2025 remains unchanged, with expected revenues between $126.5 million and $130 million, and adjusted EBITDA forecasted between $19 million and $21 million.New Customer Agreements and Partnerships
Lifecore signed multiple new agreements with both new and existing customers, including a significant agreement with Nirsum Laboratories and a post-quarter agreement with Humanetics.
Improved Financial Management
Cash flow from operations turned positive at $2 million, despite legacy legal expenses, and the company is on track to be cash flow positive in the second half of the fiscal year.
Strategic Focus and Future Growth Plans
Lifecore is focused on a 12% revenue CAGR and increasing EBITDA margins to over 25% over the next few years, with significant advancements in their late-stage pipeline towards commercialization.
Operational Efficiencies and Cost Reductions
Lifecore made substantial improvements in reducing operational expenses, improving productivity, and enhancing fermentation processing efficiency.
---
LFCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LFCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 03, 2025 | $6.81 | $5.29 | -22.32% |
| Jan 02, 2025 | $6.66 | $7.62 | +14.41% |
| Oct 04, 2024 | $4.70 | $5.38 | +14.47% |
| Aug 26, 2024 | $6.34 | $4.74 | -25.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lifecore Biomedical (LFCR) report earnings?
Lifecore Biomedical (LFCR) is schdueled to report earning on Aug 27, 2025, TBA Not Confirmed.
What is Lifecore Biomedical (LFCR) earnings time?
Lifecore Biomedical (LFCR) earnings time is at Aug 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LFCR EPS forecast?
LFCR EPS forecast for the fiscal quarter 2025 (Q4) is -0.1.
---